NASDAQ:SLXP - Salix Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$172.81
Today's RangeN/A
52-Week Range$86.00 - $172.98
VolumeN/A
Average Volume4.96 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Receive SLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for SLXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:SLXP
CUSIP79543510
Phone+1-919-8621000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Salix Pharmaceuticals (NASDAQ:SLXP) Frequently Asked Questions

What is Salix Pharmaceuticals' stock symbol?

Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."

Has Salix Pharmaceuticals been receiving favorable news coverage?

Media coverage about SLXP stock has been trending somewhat positive this week, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Salix Pharmaceuticals earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the stock's share price in the next few days.

What other stocks do shareholders of Salix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Salix Pharmaceuticals investors own include Baidu (BIDU), Gilead Sciences (GILD), Allergan (AGN), Qihoo 360 Technology (QIHU), 3D Systems (DDD), Michael Kors (KORS), Johnson & Johnson (JNJ), Intercept Pharmaceuticals (ICPT), Visa (V) and Palo Alto Networks (PANW).

How do I buy shares of Salix Pharmaceuticals?

Shares of SLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Salix Pharmaceuticals' official website?

The official website for Salix Pharmaceuticals is http://www.salix.com.

How can I contact Salix Pharmaceuticals?

Salix Pharmaceuticals' mailing address is 8510 Colonnade Center Dr, RALEIGH, NC 27615-3050, United States. The specialty pharmaceutical company can be reached via phone at +1-919-8621000.


MarketBeat Community Rating for Salix Pharmaceuticals (NASDAQ SLXP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  673
MarketBeat's community ratings are surveys of what our community members think about Salix Pharmaceuticals and other stocks. Vote "Outperform" if you believe SLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel